Core Viewpoint - Xiamen Securities Regulatory Bureau issued a warning letter to Huafu Securities for failing to perform due diligence in its role as the sponsor for Jiangping Biological's private placements, leading to undisclosed false information in the company's financial documents [1][3]. Group 1: Regulatory Actions - Huafu Securities was found to have not adequately verified Jiangping Biological's information disclosure and private placement application documents during two fundraising rounds in 2021 and 2022 [2][3]. - The warning letter will be recorded in Huafu Securities' integrity file as part of the regulatory measures taken by the Xiamen Securities Regulatory Bureau [3]. Group 2: Financial Misconduct - Jiangping Biological inflated its reported revenue by CNY 147 million and CNY 152 million for the years 2021 and 2022, respectively, which accounted for 68.62% and 64.87% of the company's disclosed revenues for those years [3]. - The company also inflated its total profit by CNY 589.4 million and CNY 569.1 million for 2021 and 2022, representing 130.43% and 119.77% of the reported total profits for those years [3]. Group 3: Penalties Imposed - The Xiamen Securities Regulatory Bureau imposed a total fine of CNY 12.6 million on Jiangping Biological's former executives, including the chairman, general manager, and other key personnel, for their involvement in the financial misconduct [3].
涉江平生物定向发行说明书财务造假 华福证券未勤勉尽责被出具警示函
Xin Lang Zheng Quan·2025-11-15 03:14